Cover Image

Oral vinorelbine: its role in advanced breast cancer pre-treated with anthracycline and taxane chemotherapies

Fausto Petrelli, Sandro Barni
  • Fausto Petrelli
    Oncology Unit, Treviglio Hospital, Treviglio, Italy |
  • Sandro Barni
    Oncology Unit, Treviglio Hospital, Treviglio, Italy


Metastatic breast cancer (BC) remains an incurable disease and clinical benefit and prolongation of time to progression are the main end-points in advanced setting. A safe and feasible schedule of administration is the principal option in pre-treated and symptomatic patients, as in the elderly too. Oral vinorelbine represents a good choice for its toxicity profile and activity in anthracycline and taxane-pre-treated BC patients. A 20–30% response rate (RR) can be obtained when used as single agent. In phase II trials, involving fit patients, and when oral vinorelbine is used in combination with other agents (e.g., capecitabine) a RR of 50-60% has been observed. In HER2-positive BC a combination of oral vinorelbine and trastuzumab has a dramatic activity in first-line therapy and is a reasonable choice in trastuzumab pre-treated patients. In conclusion, oral vinorelbine represents a pivotal choice in advanced and pre-treated BC both as single agent and in combination with others.


Breast cancer - Metastatic - Anthracycline - Taxane - Pre-treated patients - Oral vinorelbine

Full Text:

Submitted: 2011-12-05 11:29:41
Published: 2011-12-05 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Copyright (c) 2011 Fausto Petrelli, Sandro Barni

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185